Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Fan, Mengchen ^a   Xu, Haochen ^a   Wang, Lixiang ^a   Luo, Haiyu ^a   Zhu, Ximin ^a   Cai, Ping ^a   Wei, Lixiang ^a   Lu, Lu ^a   Cao, Yongliang ^a   Ye, Rong ^a   Fan, Wenying ^a   Zhao, Bing Qiao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NR2B NMDA RECEPTOR; PROTEIN BINDING; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; TOXICITY AND INTOXICATION;

ADAMTS13 PROTEIN; ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; FIBRIN; MALE; MICE; NEUROTOXICITY SYNDROMES; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84968820950     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25971     Document Type: Article

References (46)

1. Campbell, B. C. et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. Campbell BC et al. N. Engl. J. Med. 372, 1009-1018 (2015).
2. Berkhemer, O. A. et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 372, 11-20 (2015).
3. Fonarow, G. C. et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 311, 1632-1640 (2014).
4. Del Zoppo, G. J., Saver, J. L., Jauch, E. C. & Adams, H. P. Jr. & American Heart Association Stroke, C. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 40, 2945-2948 (2009).
5. Wang, Y. F. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228-231 (1998).
6. Nagai, N., Vanlinthout, I. & Collen, D. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 100, 2541-2546 (1999).
7. Armstead, W. M. et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat. Neurosci. 9, 1150-1155 (2006).
8. Yepes, M. et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96, 569-576 (2000).
9. Yepes, M. et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J. Clin. Invest. 109, 1571-1578 (2002).
10. Dong, J. F. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100, 4033-4039 (2002).
11. Zheng, X. L. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost. 11, Suppl 1, 11-23 (2013).
12. Bongers, T. N. et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis. 207, 250-254 (2009).
13. Andersson, H. M. et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 119, 1555-1560 (2012).
14. Zhao, B. Q. et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 114, 3329-3334 (2009).
15. De Meyer, S. F. et al. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 120, 5217-5223 (2012).
16. Wang, L. et al. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. Ann. Neurol. 73, 189-198 (2013).
17. Liu, D. et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat. Med. 10, 1379-1383 (2004).
18. Tang, X. N., Liu, L., Koike, M. A. & Yenari, M. A. Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke. Ther. Hypothermia. Temp. Manag. 3, 74-83 (2013).
19. Puyal, J., Vaslin, A., Mottier, V. & Clarke, P. G. Postischemic treatment of neonatal cerebral ischemia should target autophagy. Ann. Neurol. 66, 378-389 (2009).
20. Wang, X. et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35, 2726-2730 (2004).
21. Baron, A. et al. NR2D-containing NMDA receptors mediate tissue plasminogen activator- promoted neuronal excitotoxicity. Cell. Death. Differ. 17, 860-871 (2010).
22. Shi, Z. Q. et al. S-nitrosylated SHP-2 contributes to NMDA receptor-mediated excitotoxicity in acute ischemic stroke. Proc. Natl. Acad. Sci. USA 110, 3137-3142 (2013).
23. Pawlak, R., Melchor, J. P., Matys, T., Skrzypiec, A. E. & Strickland, S. Ethanol- withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B- containing NMDA receptors. Proc. Natl. Acad. Sci. USA 102, 443-448 (2005).
24. Kidwell, C. S. et al. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc. Dis. 25, 338-343 (2008).
25. Polavarapu, R. et al. Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. Blood 109, 3270-3278 (2007).
26. Nicole, O. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7, 59-64 (2001).
27. Nagai, N., De Mol, M., Lijnen, H. R., Carmeliet, P. & Collen, D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99, 2440-2444 (1999).
28. Nedergaard, M., Takano, T. & Hansen, A. J. Beyond the role of glutamate as a neurotransmitter. Nat. Rev. Neurosci. 3, 748-755 (2002).
29. Besancon, E., Guo, S., Lok, J., Tymianski, M. & Lo, E. H. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trend.s Pharmacol. Sci. 29, 268-275 (2008).
30. Lipton, S. A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug. Discov. 5, 160-170 (2006).
31. Taghibiglou, C. et al. Role of NMDA receptor-dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries. Nat. Med. 15, 1399-1406 (2009).
32. Kaur, J., Zhao, Z., Klein, G. M., Lo, E. H. & Buchan, A. M. The neurotoxicity of tissue plasminogen activator? J. Cereb. Blood. Flow. Metab. 24, 945-963 (2004).
33. Roussel, B. D. et al. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. J. Cell. Sci. 124, 2070-2076 (2011).
34. Madden, D. R. The structure and function of glutamate receptor ion channels. Nat. Rev. Neurosci. 3, 91-101 (2002).
35. Chen, M. et al. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke. 39, 3042-3048 (2008).
36. Mishra, V., Verma, R., Singh, N. & Raghubir, R. The neuroprotective effects of NMDAR antagonist, ifenprodil and ASIC1a inhibitor, flurbiprofen on post-ischemic cerebral injury. Brain. Res. 1389, 152-160 (2011).
37. Norris, E. H. & Strickland, S. Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc. Natl. Acad. Sci. USA 104, 13473- 13478 (2007).
38. Won, S., Lee, J. H., Wali, B., Stein, D. G. & Sayeed, I. Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway. J. Cereb. Blood. Flow. Metab. 34, 72-80 (2014).
39. Zhao, B. Q. et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12, 441-445 (2006).
40. Choudhri, T. F. et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J. Clin. Invest. 102, 1301-1310 (1998).
41. Himori, N. et al. Dextrorphan attenuates the behavioral consequences of ischemia and the biochemical consequences of anoxia: possible role of N-methyl-d-aspartate receptor antagonism and ATP replenishing action in its cerebroprotecting profile. Psychopharmacology. 111, 153-162 (1993).
42. Korninger, C. & Collen, D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 46, 561-565 (1981).
43. Chopp, M., Zhang, R. L., Zhang, Z. G. & Jiang, Q. The clot thickens-thrombolysis and combination therapies. Acta. Neurochir. Suppl. 73, 67-71 (1999).
44. Meng, W. et al. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J. Cereb. Blood. Flow. Metab. 19, 1316- 1321 (1999).
45. Kilic, E., Kilic, U., Bahr, M. & Hermann, D. M. Tissue plasminogen activator-induced ischemic injury is reversed by NMDA antagonist MK-801 in vivo. Neurodegener. Dis. 2, 49-55 (2005).
46. Fan, W. et al. Caspase-3 modulates regenerative response after stroke. Stem Cells 32, 473-486 (2014).